SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending amidst discussions about its valuation, partnership with Nvidia, and significant deals with major industry players like OpenAI and Microsoft. Community members are debating the sustainability of GPU pricing and the potential impact of debt, while others focus on the company's growth prospects within the AI infrastructure sector. Bullish investors highlight long-term potential and reiterate the stock's connection to the AI revolution.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its skin drug, sonelokimab, leading to community speculation about a potential buyout and significant gains. While some express concern over placebo responses in the trial, many believe the overall results position the drug as best-in-class, igniting discussions about its market potential and future FDA approval. The community is closely watching for further developments, including corporate announcements and potential M&A activity.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin is gaining traction, with the community rallying behind its unique branding and "caw caw" battle cry. Active discussion revolves around its potential as a multichain gem and its strong, engaged community. Some users highlight the token's burn mechanisms.

abrdn ETF - abrdn Physical Platinum Shares ETF

PPLT is trending as traders assess whether it's undervalued relative to gold and silver, with some anticipating a breakout from a multi-year consolidation. Discussions include the potential for increased platinum demand due to industrial applications and potential supply deficits. Some traders are considering trimming their positions, while others are buying, anticipating a move towards higher price targets.

ETF Series Solutions Trust - Defiance Quantum ETF

QTUM is trending due to growing interest in quantum computing, with community members actively discussing the ETF's potential upside and its exposure to key players like IONQ and RGTI. Bullish sentiment is fueled by significant options activity and the expectation that government and commercial applications of quantum computing will expand. Some investors see it as a way to diversify into the quantum sector instead of choosing individual names.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is trending amid discussions surrounding its financial health, technical analysis indicating a potential uptrend, and unusual options activity. The community is actively discussing potential breakout levels and call option opportunities, as well as the company's legal challenges related to talc and Tylenol. Some are optimistic due to Trump's proposed tariffs potentially benefiting domestic pharma manufacturers like JNJ.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amidst discussions around its achieved quantum performance milestone and potential implications for the sector. The community is debating its valuation, future growth prospects, and competition within the quantum computing landscape, with some highlighting potential government contracts and partnerships while others express skepticism about commercial viability and dilution concerns.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as the community discusses its AI initiatives, potential partnerships, and the impact of broader economic factors like tariffs and consumer spending. Some express concerns about valuation and recent price action, while others highlight Walmart's defensive nature and long-term growth potential. Discussions also include analysis of Walmart's competitive position relative to companies like Target and Amazon.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending following recent earnings and discussions of strategic moves, including potential asset sales and partnerships, which have caught the attention of analysts and investors. Community members are weighing the potential for a short squeeze amid high institutional ownership and short interest, while also considering the impact of tariffs and potential infrastructure developments like AI data centers. Optimism is growing around the company's position in the North American steel market and potential for increased automotive production.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as the community discusses potential partnerships with Apple and TSMC, which could significantly boost its foundry business. Bullish sentiment is fueled by government support and investment from Nvidia, although some traders are wary of the stock being overbought after a recent surge. Discussions also include potential implications of geopolitical tensions, particularly concerning Taiwan, and how that may affect Intel's position in the chip manufacturing landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/09/3095729/33090/en/Axsome-Therapeutics-Provides-Update-on-the-New-Drug-Application-NDA-for-AXS-14-for-the-Management-of-Fibromyalgia.html">said</a> that it has received a Refusal-to-File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its application for a drug approval to treat fibromyalgia.The FDA issues refuse-to-file letters if it identifies deficiencies in a company’s application for drug approval.The agency said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.The FDA noted that it does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at eight weeks, and it used a flexible-dose paradigm.The agency, however, opined that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. Both studies yielded positive results. &nbsp;To address the FDA’s feedback, Axsome will conduct an additional controlled trial, utilizing a fixed-dose paradigm and a 12-week primary endpoint. The company anticipates initiating the new trial in the fourth quarter of 2025.CEO Herriot Tabuteau said that the company is “well-positioned” to initiate the new trial.Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from the disorder.On Stocktwits, retail sentiment around Axsome stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_09_at_8_04_44_AM_png_5593dd0fd5.webp" alt="AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the possibility for the company achieving profitability by the end of the year is “out the window.”<stembedurl>https://stocktwits.com/GrayCapital/message/617244353</stembedurl>Another user, however, brushed it off as a “small delay.”<stembedurl>https://stocktwits.com/cadbrad1/message/617242242</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> has risen by about 28% this year and by about 56% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-us-china-talks/chlEazYRbyd">Dow Futures Edge Higher Ahead Of US-China Talks In London: WBD, Apple, Tesla Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability

The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.

Equity

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AXSM News

AXSM Axsome Therapeutics Inc